Research News on Targeted Therapies
-
Nexavar Offers No Benefits in Treating Advanced-Stage Disease
A small, early study suggests that Nexavar offers no benefits for advanced-stage breast cancer treatment.
-
Chemo Plus Herceptin Can Put Metastatic, HER2-Positive Disease Into Remission
Some metastatic, HER2-positive breast cancers will respond to Herceptin for several years, suggesting that long-term remission is possible.
-
Afinitor Added to Aromasin Slows Advanced-Stage Breast Cancer Growth
A study showed that postmenopausal women with advanced breast cancer who took Afinitor (chemical name: everolimus) with the aromatase inhibitor Aromasin (chemical name: exemestane) appeared to have longer progression-free survival compared to women taking Aromasin with a placebo.
-
Tykerb Alone Doesn’t Work as Well as Herceptin Alone to Treat Early-Stage, HER2-Positive Disease
Early results from the ALTTO study show that Tykerb doesn't work as well as Herceptin when given alone after surgery to treat early-stage, HER2-positive breast cancer.
-
Older Women with Existing Heart Problems, Diabetes Have Higher Risk of Heart Function Problems with Herceptin
A small study suggests that women 70 and older who have existing heart problems or diabetes are more likely to develop heart problems if treated with Herceptin for breast cancer.
-
National Comprehensive Cancer Network Continues Support of Avastin for Metastatic Breast Cancer
The National Comprehensive Cancer Network continues to support Avastin to treat certain metastatic breast cancers.
-
Afinitor Study Stopped Early Because of Good Results
A study looking at the benefits of Afinitor to treat certain advanced-stage and metastatic breast cancers was stopped early because of good results.
-
Medicare Will Continue Paying for Avastin to Treat Metastatic Breast Cancer
Medicare has announced that it will continue to pay for Avastin to treat metastatic breast cancer.
-
FDA Expert Panel Recommends Removing Breast Cancer Indication from Avastin
An FDA advisory committee unanimously recommended that Avastin should no longer be approved to treat metastatic, HER2-negative breast cancer.
-
Iniparib Doesn’t Seem to Help Treat Metastatic, Triple-Negative Disease
Results suggest that adding iniparib to chemotherapy doesn't help treat metastatic, triple-negative breast cancer.
